- Subject
- Nutrition
- Filed
- Source
- vcramer
- Loans
- 812
Islet Transplant Access Could Change for Some Adults With Type 1 Diabetes
The ADA supports organ-based oversight for donor islet cells, while calling for careful eligibility rules and better insurance coverage.

A proposed change to how deceased-donor islet cells are overseen could reduce barriers to transplantation for a small group of adults with type 1 diabetes. The American Diabetes Association (ADA) says unmodified donor islets could be managed within an organ-transplant framework, while manufactured or substantially altered cell products should remain under separate Food and Drug Administration oversight.

The ADA submitted comments to the U.S. Department of Health and Human Services (HHS) in response to a request for information about improving access to deceased-donor islet cells and cell products. The comments describe a possible route for addressing a mismatch in the current system: donor islet cells are treated as biologic drugs, even though they are transplanted cells obtained from deceased donors. The ADA argues that this classification creates access barriers for people who may be candidates for the procedure.
Who might benefit
Islet transplantation is relevant to a narrowly defined group of adults with type 1 diabetes who continue to experience repeated severe hypoglycemia despite intensive diabetes management and education. For some, these episodes make it difficult or unsafe to reach blood glucose targets. The ADA supports limiting any change to people whose eligibility fits the population studied in a National Institutes of Health (NIH) Phase III clinical trial.
That boundary matters. The proposal concerns access to an established type of donor-cell transplantation for selected patients; it does not establish that transplantation is appropriate for most people with type 1 diabetes. The ADA describes potential benefits for eligible recipients, including fewer severe hypoglycemic events and improved quality of life. The material provided does not give trial size, outcome rates, or details about risks, so those results cannot be quantified here.
Different oversight for different products
For unmodified islets from deceased donors, the ADA supports oversight as organs through the Health Resources and Services Administration (HRSA) and the Organ Procurement and Transplantation Network (OPTN). Its position draws a distinction between these donor cells and products that have been further manipulated, as well as stem cell-derived islets and other manufactured cell therapies. The ADA says those products should continue to receive Food and Drug Administration oversight.
This distinction reflects how the cells are sourced and processed. A transplant system can coordinate donor recovery, allocation, and transplant care, while additional processing or a manufactured origin may require a different oversight pathway. The ADA's comments support a targeted adjustment for deceased-donor islets rather than a broad change covering all cell-based treatments.
Existing systems and international experience
The ADA points to Canada and the United Kingdom as relevant examples. In both countries, islets are overseen through organ and tissue transplantation frameworks. The association says these systems have national quality standards for islet isolation and established clinical transplantation programs with documented patient outcomes.
It also argues that parts of the needed U.S. infrastructure already exist. HRSA and the OPTN support related work through pancreas procurement and allocation systems, performance measures for organ procurement organizations, and waitlisting for islet transplant candidates. Those systems may provide a foundation for implementation, although the comments do not spell out how a new pathway would be put into practice or what additional resources it might require.
Coverage remains a separate barrier
A revised oversight pathway alone would not ensure that eligible patients can receive a transplant. The ADA also calls attention to insurance coverage, including the current limit on Medicare coverage for islet transplantation to NIH-sponsored clinical trials. It urges HHS to consider coverage barriers alongside the regulatory question.
For patients and families, the practical takeaway is that this discussion concerns how a possible treatment is organized and paid for, not a change in individual care decisions today. Anyone with recurrent severe hypoglycemia can discuss available treatment options with their diabetes care team. A clinician can assess whether specialist evaluation is appropriate and explain the potential benefits, risks, eligibility requirements, and coverage considerations for transplantation.
The HHS request for information is described as a next step after advocacy by the ADA and the diabetes community. In a June letter to HHS, the ADA had called for action on the classification barrier. The comments now set out the association's preferred approach: organ-based oversight for unmodified deceased-donor islets, continued oversight for other cell products, eligibility limited to a studied patient group, and attention to coverage. Whether those elements lead to a workable pathway will depend on the next steps in the review and implementation process.